pharmacology
Can a hydrogen sulfide donor protect the liver from cyclophosphamide?
Open access · cc by · source: Europe PMC
In rats, 10-day NaHS pretreatment lowered CP-driven ALT/AST spikes and suppressed TLR2/4–JNK/NF-κB inflammatory signaling linked to hepatotoxicity.
Key findings
CP raised ALT/AST; NaHS reduced enzymes (e.g., ALT 33.24 vs 49.57 U/L) and suppressed TLR2/4 with downstream JNK and NF-κB.
Methodology
They randomized rats into control, CP, NaHS+CP, and PAG+CP groups (n=6 each), gave NaHS or PAG for 10 days, then a single CP 200 mg/kg dose, and measured liver enzymes and TLR pathway markers.
Limitations
Rodent enzyme/pathway changes do not establish a clinical dosing regimen or human oncology safety for NaHS.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Related papers in this topic
Same topic cluster — not a recommendation engine.